Subtype
Neuroendocrine Carcinoma
CI-CAN-00001275NECExplore in graph →
515 active trials12 approved drugs28 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001275NECExplore in graph →
Clinical trials
1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (213)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00654238 | Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer | completed | Phase 2 | 59 | University of PennsylvaniaOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT01999881 | Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients | completed | N/A | 21 | University of Wisconsin, MadisonOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT00617409 |
| To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid |
| completed |
| Phase 2 |
| 69 |
| H. Lee Moffitt Cancer Center and Research InstituteOTHER |
| 1 |
| Nov 8, 2019 |
| clinicaltrials |
| NCT02511795 | AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | completed | Phase 1 | 128 | AstraZenecaINDUSTRY | 2 | Nov 7, 2019 | clinicaltrials |
| NCT00547651 | AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy | completed | Phase 3 | 637 | CelgeneINDUSTRY | 17 | Nov 6, 2019 | clinicaltrials |
| NCT00375193 | Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy | completed | Phase 2 | 75 | CelgeneINDUSTRY | 3 | Oct 24, 2019 | clinicaltrials |
| NCT00923884 | Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer | completed | — | 546 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2019 | clinicaltrials |
| NCT00483509 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma(NGR007) | completed | Phase 2 | 28 | AGC Biologics S.p.A.INDUSTRY | 1 | Oct 4, 2019 | clinicaltrials |
| NCT01025284 | A Study for Participants With Small-Cell Lung Cancer | completed | Phase 2 | 64 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 17, 2019 | clinicaltrials |
| NCT02250885 | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | completed | Phase 2 | 14 | Gabrail Cancer Center ResearchOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT02949895 | Study of BMS-986012 in Subjects With Small Cell Lung Caner | completed | Phase 1 | 7 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 12, 2019 | clinicaltrials |
| NCT01266447 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT01439568 | A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT03092739 | A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens | completed | — | 184 | Hoffmann-La RocheINDUSTRY | 6 | Jul 23, 2019 | clinicaltrials |
| NCT01603004 | Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors | completed | — | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT01040312 | An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors | completed | — | 321 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | May 23, 2019 | clinicaltrials |
| NCT02069158 | Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor(IOSI-NDU-001) | completed | Phase 1 | 17 | Cristiana SessaOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT02586350 | Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) | completed | Phase 2 / Phase 3 | 91 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT03059797 | Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) | completed | Phase 2 | 120 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT01253369 | Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01173523 | Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 25 | David M. Jackman, MDOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02457273 | Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients | completed | Phase 2 | 23 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT01069653 | Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer | completed | Phase 1 | 9 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT03239171 | Bioinformation Therapy for Lung Cancer | completed | Phase 2 / Phase 3 | 120 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 113 | PfizerINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT00309959 | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01497873 | A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer | completed | Phase 2 | 164 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Dec 27, 2018 | clinicaltrials |
| NCT02038647 | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 178 | Millennium Pharmaceuticals, Inc.INDUSTRY | 10 | Dec 27, 2018 | clinicaltrials |
| NCT03085849 | SGI-110 Plus Durvalumab/Tremelimumab in SCLC | completed | Phase 1 | 2 | Catherine ShuOTHER | 1 | Dec 10, 2018 | clinicaltrials |
| NCT02200081 | Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC(IMPULSE) | completed | Phase 2 | 103 | Mologen AGINDUSTRY | 4 | Nov 15, 2018 | clinicaltrials |
| NCT00926640 | A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2018 | clinicaltrials |
| NCT02913443 | A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC) | completed | Phase 1 | 18 | Hoffmann-La RocheINDUSTRY | 5 | Oct 19, 2018 | clinicaltrials |
| NCT02874664 | A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer | completed | Phase 1 | 46 | StemcentrxINDUSTRY | 2 | Sep 24, 2018 | clinicaltrials |
| NCT01881906 | Exercise in Advanced Stage Lung Cancer Patients(EXHALE) | completed | N/A | 219 | Rigshospitalet, DenmarkOTHER | 1 | Sep 6, 2018 | clinicaltrials |
| NCT01901653 | Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 82 | StemcentrxINDUSTRY | 1 | Aug 9, 2018 | clinicaltrials |
| NCT01457469 | Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer | completed | Phase 1 | 6 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT00298896 | Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer | completed | Phase 2 | 55 | Sunesis PharmaceuticalsINDUSTRY | 2 | Jul 26, 2018 | clinicaltrials |
| NCT00098956 | 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2018 | clinicaltrials |
| NCT00527735 | Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 334 | Bristol-Myers SquibbINDUSTRY | 8 | Jul 18, 2018 | clinicaltrials |
| NCT01553916 | Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain | completed | Phase 1 / Phase 2 | 19 | Washington University School of MedicineOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01931787 | CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 1 | 15 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT02977845 | Effect of Qigong on the Symptom Clusters of Dyspnea, Fatigue, and Anxiety. | completed | N/A | 162 | Nam Dinh University of NursingOTHER | 1 | Jun 28, 2018 | clinicaltrials |
| NCT02035657 | A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma | completed | Phase 1 | 10 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jun 13, 2018 | clinicaltrials |
| NCT00445198 | A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies | completed | Phase 1 / Phase 2 | 86 | AbbVie (prior sponsor, Abbott)INDUSTRY | 3 | Jun 6, 2018 | clinicaltrials |
| NCT02465424 | Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients(QaLM) | completed | — | 173 | Velindre NHS TrustOTHER_GOV | 1 | May 22, 2018 | clinicaltrials |
| NCT01424878 | Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients | completed | — | 150 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2018 | clinicaltrials |
| NCT01866228 | Clinical Trial of the Impact of Treatment Consultation Recordings on Cancer Patient Outcomes | completed | N/A | 140 | University of ManitobaOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT03419286 | Transformation Into Small Cell Lung Cancer : a Mode of Resistance to Treatment(TransCPC) | completed | — | 62 | University Hospital, GrenobleOTHER | 0 | Feb 1, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Nov 18, 2019source: clinicaltrials